Evidence map›Paper›PMID 39136880›Full record

ArticleEJNMMI research2024

Enhancing [

Jordan Cheng, Joke Zink, Edward O'Neill, Bart Cornelissen, Julie Nonnekens, Lefteris Livieratos, Samantha Y A Terry

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Progress in the application ofAnnals of nuclear medicine · 2026
    Review
  2. Combination therapy strategies in engineeredCell communication and signaling : CCS · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jordan ChengDepartment of Imaging Chemistry and Biology, School of Biomedical Engineering and Imaging Sciences, King's College London, London, SE1 7EH, UK.
Joke ZinkDepartment of Molecular Genetics, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.
Edward O'NeillNuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.
Bart CornelissenDepartment of Nuclear Medicine, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Julie NonnekensDepartment of Molecular Genetics, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.
Lefteris LivieratosDepartment of Biomedical Engineering, School of Biomedical Engineering and Imaging Sciences, King's College London, London, SE1 7EH, UK.
Samantha Y A TerryDepartment of Imaging Chemistry and Biology, School of Biomedical Engineering and Imaging Sciences, King's College London, London, SE1 7EH, UK. samantha.terry@kcl.ac.uk.ORCID http://orcid.org/0000-0002-6497-6681

Funding

Cancer Research UK C7893/A28990Engineering and Physical Sciences Research Council EP/S032789/1European Research Council 101042537;RADIOBIOMedical Research Council MR/N013700/1Rosetrees Trust PhD2022\100001Wellcome TrustWellcome Trust WT203148/Z/16/ZWellcome Trust WT212885/Z/18/Z
6 · The paper itself

Abstract

backgroundPeptide receptor radionuclide therapy (PRRT) uses [

resultsTransfected human osteosarcoma (U2OS + SSTR2A, high SSTR2A expression) and pancreatic NET (BON1 + STTR2A, medium SSTR2A expression) cells were subjected to hydroxyurea, gemcitabine or triapine for 24 h at 37

conclusionsHydroxyurea, gemcitabine and triapine all increased cell size, SSTR2A expression, and [

Indexed as

Cell cycleCell sizeCombination treatmentTargeted radionuclide therapyViability

Identifiers

PMID39136880
PMCPMC11322472

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.